Differences in the cost of antidepressants across state medicaid programs

Journal of Mental Health Policy and Economics

Volumn 11, Issue 1, 2008, Pages 33-47

  Kelton, Christina M L ^a   Rebelein, Robert P ^b   Heaton, Pamela C ^a   Ferrand, Yann ^a   Guo, Jeff J ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b VASSAR COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANAFRAMIN; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; GENERIC DRUG; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TORFRANIL; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VANATRIP; VENLAFAXINE;

ARTICLE; CAPITAL; COST BENEFIT ANALYSIS; DEPRESSION; DRUG COST; DRUG UTILIZATION; ECONOMIC EVALUATION; EMPLOYMENT; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; MEDICAID; PRESCRIPTION; REIMBURSEMENT; RURAL AREA; UNITED STATES; URBANIZATION;

ANTIDEPRESSIVE AGENTS; COST CONTROL; DEPRESSIVE DISORDER; HEALTH POLICY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MEDICAID; STATE GOVERNMENT; UNITED STATES;

EID: 42949119721     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Adelmann PK. Mental and substance use disorders among Medicaid recipients: prevalence estimates from two national surveys. Adm Policy Ment Health 2003; 31(2): 111-129.
2. Katon W, Sullivan M, Walker E. Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. Ann Intern Med 2001;134: 917-925.
3. Kendrick T. Primary care options to prevent mental illness. Ann Med 1999; 31: 359-363.
4. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36.
5. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety 1997; 6: 10-18.
6. Henry JA, Alexander CA, Sener, EK. Relative mortality from overdose of antidepressants. Br Med J 1995; 310: 221-224.
7. Helms K, Anderson LA. Overview of selective serotonin reuptake inhibitors (SSRIs). Clinical Pharmacology, Version 2.20. Internet address: http://www.goldstandard.com/. (Accessed April 2007.)
8. Chen Y, Kelton CML, Jing Y, Guo JJ, Li X, Patel NC. Utilization, price, and spending trends for antidepressants in the U.S. Medicaid program. Res Soc Admin Pharm 2007; in press.
9. Cook A. How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry, Congressional Budget Office Report, 1998.
10. Guo JJ, Kelton CML, Pasquale MK, Zimmerman J, Patel A, Heaton PC, Cluxton RJ. Price and market-share competition of firms selling anti-ulcer gastric medications in the Ohio Medicaid market. Int J Pharm Med 2004; 18(5): 271-282.
11. Dusing ML, Guo JJ, Kelton CML, Pasquale MK. Competition and price discounts for a hospital buyer in the anti-infective pharmaceutical market. J Pharm Finance Econ Policy 2005; 14(2): 59-85.
12. Fischer MA, Avorn I. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res 2003; 38: 1051-1063.
13. Moore WJ, Gutermuth K, Pracht EE. Systemwide effects of Medicaid retrospective Drug Utilization Review programs. J Health Polit Policy Law 2000; 25: 653-690.
14. Centers for Medicare & Medicaid Services. State Drug Utilization Data. Internet address: http://www.cms.hhs.gov/MedicaidDrugRebateProgram/ SDUD/list.asp#TopOfPage (Accessed November 2006.)
15. National Pharmaceutical Council, Inc. Pharmaceutical Benefits Under State Medical Assistance Programs, 2004, Reston, Virginia, 2005.
16. Kaiser Commission on Medicaid and the Uninsured. Medicaid Outpatient Prescription Drug Benefits: Findings from a National Survey, 2003, Washington, D.C., 2003.
17. Kaiser Commission on Medicaid and the Uninsured. Medicaid Outpatient Prescription Drug Benefits: Findings from a National Survey and Selected Case Study Highlights, Washington, D.C., 2001.
18. National Oceanic and Atmospheric Administration National Data Centers, U.S. Department of Commerce. Sunshine-Average Percent of Possible. Internet address: http://www.ncdc.noaa.gov/oa/climate/online/ccd/ pctpos.txt (Accessed November 2006.)
19. Bureau of Labor Statistics, U.S. Department of Labor. Regional and State Employment and Unemployment, July 2003, Table 4, Employees on Nonfarm Payrolls by State and Selected Areas, Not Seasonally Adjusted. Internet address: http://www.bls.gov/news.release/archives/laus_08192003.pdf (Accessed November 2006.)
20. Federal Trade Commission. Generic Drug Entry Prior to Patent Expiration: An FTC Study. July 2002. Available at: http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf. Accessed April 30, 2007.
21. Food and Drug Administration. FDA Approves the First Drug for Seasonal Depression. Internet address: http://www.fda.gov/bbs/topics/NEWS/2006/ NEW01388.html (Accessed April 2007.)
22. Martin JL, Marler MR, Harker JO, Josephson KR, Alessi CA. A multicomponent nonpharmacological intervention improves activity rhythms among nursing home residents with disrupted sleep/wake patterns. J Gerontol 2007; 62A(1): 67-72.
23. Probst JC, Laditka SB, Moore CG, Harun N, Powell MP, Baxley, EG. Rural-urban differences in depression prevalence: implications for family medicine. Fam Med 2006; 38(9): 653-660.